Merck & Co. Inc. / SmartCells, Inc.

Diabetes Mellitus (Type 1 and insulin-treated Type 2)

$37.6B Global type 1 diabetes market 2025 (forecast)

Disease Overview

Diabetes mellitus is a chronic disorder of insulin action or production. Insulin-treated patients face a tight balance between hyperglycemia (driving long-term complications) and hypoglycemia (driving acute hospitalization and death). A glucose-responsive insulin would, in principle, dose itself in real time and eliminate hypoglycemia risk.

Competitive Landscape

At deal time (December 2010), the insulin market was dominated by Sanofi's Lantus (insulin glargine), Novo Nordisk's NovoLog/Levemir, and Lilly's Humalog/Humulin. Innovation focused on longer-acting analogs (e.g., Tresiba, approved 2015) and ultra-rapid analogs, plus emerging closed-loop pump systems. SmartCells' SmartInsulin proposed a fundamentally different paradigm: a chemically-modified insulin that auto-regulates release based on glucose concentration, theoretically eliminating hypoglycemia. The Merck deal — over $500M for a preclinical asset on $10M of capital raised — reflected scarcity of differentiated insulin innovation. Merck advanced the candidate as MK-2640 into a Phase 1 trial that completed in 2016, then terminated development for lack of efficacy. The failure preserved the existing analog/closed-loop competitive structure and shifted glucose-responsive insulin work to academic and biotech follow-ons (e.g., Merck's later licensing back to Zion's Akston Biosciences).